







Presentation and Discussion of the Research Paper

# The Effects of PEGylation on LNP Based mRNA Delivery To The Eye

By: Anfal Ibrahim

Research Topic & Seminar (501)

Tue 15<sup>th</sup> of June 2021



# Outline

## I. Introduction

- A. PEGylation
- B. Lipid Nanoparticles

## II. Material and Method

- A. Animals Selection
- B. Nanoparticle Formulation and Characterization
- C. Injections
- D. In-vivo Bioluminescent Imaging
- E. Fundus Photography
- F. Immunohistochemistry

## III. Result and Discussion

- A. The Effects of LNP size and Cholesterol Modification Post-subretinal Injection
- B. The Effects of LNP size and DSPE Modification Post-subretinal Injection
- C. The Effects of LNP size and Cholesterol Modification Post-intravitreal Injection
- D. The Effects of LNP size and DSPE Modification Post-intravitreal Injection

## IV. Conclusion

- A. About the Approach

## V. References



## The effects of PEGylation on LNP based mRNA delivery to the eye

Renee C. Ryals<sup>1</sup>, Siddharth Patel<sup>2</sup>, Chris Acosta<sup>2</sup>, Madison McKinney<sup>2</sup>, Mark E. Pennesi<sup>1</sup>, Gaurav Sahay<sup>1,2\*</sup>

**1** Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States of America,

**2** Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon, United States of America

### Abstract

Gene therapy is now an effective approach to treat many forms of retinal degeneration. Delivery agents that are cell-specific, allow for multiple dosing regimens, and have low immunogenicity are needed to expand the utility of gene therapy for the retina. We generated eight novel lipid nanoparticles (LNPs) ranging in size from 50 nm to 150 nm by changing the PEG content from 5% to 0.5%, respectively. Subretinal injections of LNP-mRNA encoding luciferase revealed that 0.5% PEG content within nanoparticles elicits the highest expression. Similar injections of LNP delivered cre mRNA into Ai9 mice revealed cell-specific protein expression in the retinal pigment epithelium (RPE), confirmed by fundus photography and immunohistochemistry of whole globe cross-sections. To investigate mechanisms of LNP delivery to the eye, we injected mCherry mRNA using the subretinal approach in *apoE*<sup>-/-</sup> and *Mertk*<sup>-/-</sup> mice. RPE transfection was observed in both mouse models suggesting that LNP intracellular delivery is not solely dependent on apolipoprotein adsorption or phagocytosis. To investigate LNP penetration, particles were delivered to the vitreous chamber via an intravitreal injection. The 0.5% PEG particles mediated the highest luciferase activity and expression was observed in the Müller glia, the optic nerve head and the trabecular meshwork, but failed to reach the RPE. Overall, particles containing less PEG (~150 nm in size) mediated the highest expression in the eye. Thus far, these particles successfully transfect RPE, Müller cells, the optic nerve head and the trabecular meshwork based on route of administration which can expand the utility of LNP-mediated gene therapies for the eye.

# Introduction

What do you know about blindness?




Fig.1 (Vision process in the eye)  
Source: American Academy of Ophthalmology

## Retinal Blindness (Mutation RPE65)

How you would treat it?

## Blind People Across the World






Fig.2 (Blindness around the world)  
Source: International Center for eye Health



# Gene Therapy




Luciferin



Bioluminescent




# PEGylation



What is PEGylation?

How it works?

PEGylation is the covalent coupling of Non-Toxic Hydrophilic Poly ethylene glycol (PEG)



# Lipid Nanoparticles





Fig.5 (Lipid Nanoparticles structure)  
Source: ResearchGate




Fig.6 (Lipid Nanoparticles size)  
Source: ResearchGate

What is the role of Lipid Nanoparticles?

**Gene Delivery Vehicle**



# Animals Selection



BALB/c Mice



Produce plasmacytomas  
(monoclonal antibody)  
following injection



apoE Mice



Homozygous for ApoE<sup>tmUnc</sup>  
mutation which show increase  
in total plasma cholesterol



C57BL6 Mice



General purpose strain  
carrying both spontaneous and  
induced mutations



Mertk Mice



Exhibit an increase in spleen size and  
decrease in monocyte response and  
complete photoreceptor degradation




Ai9 Mice



Prevent transcription of  
red fluorescent protein  
variant tdTomato



# Nanoparticle Formulation and Characterization



How LNPs functioned?

LNPs Composition	Description
MC3	Unitized cationic lipids that is used for making LNPs.
DSPC	Type of phospholipid that is used for making LNPs.
DMG-PEG2k	Used with MC3 to form cationic nanoparticles that can encapsulate mRNA
L-7202	mRNA express Luciferase protein
L-7211	mRNA encoding Cre recombinase
L-7203	mRNA encoding fluorescent protein mCherry

Table.1 (Lipid Nanoparticles composition)  
Source: Anfal's

# LNPs were formulated

Microfluidic Mixing




Fig.8 (Microfluidic Mixing)  
Source: ResearchGate

Ethanol Phase	Aqueous Phase
MC3	mRNA + 50mM Citrate Buffer pH4
DSPC	
<b>DMG-PEG2K</b>	
Cholesterol	

# The percentage of DMG-PEG was changed

0.5%    1.5%    3%    5%

**Why?**





Fig.9 (Lipid Nanoparticles characterization)

Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

The LNPs solution was subjected to buffer exchange with PBS pH 7.2

# LNPs Characterization



Hydrodynamic radius




Fig.10 (Hydrodynamic Radius)  
Source: Springer Link

Dynamic Light scattering

The generated particles size range from 150nm to 50 nm




Fig.11 (Bar graph showing the size and PDI of one set of particles when percentage of PEG is increased and modulated against cholesterol)

Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye




Fig.12 (Bar graph showing the size and PDI of one set of particles when percentage of PEG is increased and modulated against DSPC)

Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye



# mRNA encapsulation efficiency was measured



Quantification RNA in solution

LNP #	DMG-PEG (%)	Cholesterol (%)	DSPC (%)	MC3 (%)	Encapsulation Efficiency (%)
1	0.5	39.5	10	50	97.8
2	1.5	38.5	10	50	96.6
3	3	37	10	50	98.4
4	5	35	10	50	94.8
5	0.5	38.5	11	50	96.2
6	1.5	38.5	10	50	95.8
7	3	38.5	8.5	50	97.2
8	5	38.5	6.5	50	97.0

Table. 2 (LNP components and characterization)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

How PEGylation and size may impact intracellular delivery?

# Injection

## Two Type of Injection

Subretinal

Intravitreal




Fig.13 (Type of injection subretinal versus intravitreal)  
Source: Mini Review Retinal Gene Therapy

## Prior to injection

Mice were administered with


0.5% proparacaine  
Eye drop numb

1% tropicamide  
Widen the pupil

2.5% phenylephrine  
Relieve sense  
congestion and pressure

Ketamine  
anesthetic

**subretinal**



2.5% hypromellose  
was placed over the eyes to relieve the dryness and  
irritation



Going through the scleral to the limbus using a  
Hamilton syringe



2% fluorescent solution was added to the PBS or  
LNPs (Luciferase – Cre – mCherry)

**Was delivered to Retina**




Fig.14 (Eyes structure)  
Source: Louisville Eye Center



**Intravitreal**





Fig.14 (Eyes structure)  
Source: Louisville Eye Center

2.5% hypromellose  
was placed over the eyes to relieve the dryness and  
irritation



Going through the scleral to the limbus using a  
Hamilton syringe



2% fluorescent solution was added to the PBS or  
LNPs (Luciferase – Cre – mCherry)

**Was delivered to vitreous chamber**

# In-vitro Bioluminescent Imaging

Mice were injected with 150mg of Luciferin



Bioluminescent imaging was conducted on the IVIS Spectrum




Fig.15 (Mice under IVIS Spectrum)  
Source: ResearchGate

**Analysis image for specific region**




Fig.16 (Mice under IVIS Spectrum)  
Source: ResearchGate

# Fundus Photography

Live retinal imaging was performed with Micron IV



Fig.17 (Fundus Photography)  
Source: New Jersey Vision Associate




Fig.18 (Micron Iv image)  
Source: The University of British Columbia

**General retinal health**

**To capture td Tomato fluorescent protein**



# Immunohistochemistry

Mouse eyes were enucleated



## Fixation

49% paraformaldehyde

## Sectioning microtome

## Staining

10% xylene – 100% ethanol – 95% ethanol  
– 80% ethanol

## Washing

Phosphate buffered saline





Fig.19 (Immunohistochemistry)  
Source: CreativeBiomart

**To show protein expression in the Retinal pigment Epithelium (RPE)**


## Two Type of Injection

Remember ...

Subretinal



Intravitreal



## 8 LNPs with Different Characterization

4 Cholesterol

4 DSPC

## Luciferase expression

apoE

Ai9

Mertk

C57BL6

# The Effects of LNP Size and Cholesterol Modification Post-subretinal Injection

LNPs Kinetic were measured  
with Luciferase assay



Luciferase activity was measurable at 4  
hours post-injection

Increased to maximum level at 24  
hours post-injection

Decreased by 48 hours post-injection

Subretinal - **↑ % PEG** **↓ % Cholesterol**

24 hours post-injection




Fig.20 (Representative image demonstrated Luciferase activity in the eye 24 hours post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye



# The Effects of LNP Size and DSPC Modification Post-subretinal Injection

LNPs Kinetic were measured with Luciferase assay



Luciferase activity was measurable at 4 hours post-injection

Increased to maximum level at 24 hours post-injection

Decreased by 48 hours post-injection

Subretinal - ↑ % PEG ↓ % DSPC

24 hours post-injection


0.5% PEG



1.5% PEG



3% PEG



5% PEG



Fig.21 (Representative image demonstrated Luciferase activity in the eye 24 hours post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

Luciferase activity plotted for each group over time (Cholesterol)




Fig.22(Luciferase activity plotted for each group over time Cholesterol)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

Luciferase activity plotted for each group over time (DSPC)




Fig.23 (Luciferase activity plotted for each group over time DSPC)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

## Top Bright Field Bottom Fundus Images After 7 Days (Cholesterol)




Fig.24 (Representative bright light top and td Tomato bottom fundus images for each group taken 7 days post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

## Top Bright Field Bottom Fundus Images After 7 Days (DSPC)




Fig.26 (Representative bright light top and td Tomato bottom fundus images for each group taken 7 days post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

## Confocal Image of Immunohistochemistry (Cholesterol)




Fig.25 (Representative confocal images of immunohistochemistry showing RFP expression in the REP for all groups)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

## Confocal Image of Immunohistochemistry (DSPC)




Fig.27 (Representative confocal images of immunohistochemistry showing RFP expression in the REP for all groups)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

# The Effects of LNP Size and Cholesterol Modification Post-intravitreal Injection

LNPs Kinetic were measured  
with Luciferase assay



Luciferase activity was measurable at 4  
hours post-injection


Increased to maximum level at 24  
hours post-injection

Decreased by 48 hours post-injection


Intravitreal - **↑ % PEG ↓ % Cholesterol**

24 hours post-injection


0.5% PEG



1.5% PEG



3% PEG



5% PEG




Fig.28 (Representative image demonstrated Luciferase activity in the eye 24 hours post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye



# The Effects of LNP Size and DSPC Modification Post-intravitreal Injection

LNPs Kinetic were measured with Luciferase assay



Luciferase activity was measurable at 4 hours post-injection

Increased to maximum level at 24 hours post-injection

Decreased by 48 hours post-injection

Intravitreal - **↑ % PEG ↓ % DSPC**




Fig.29 (Representative image demonstrated Luciferase activity in the eye 24 hours post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

Luciferase activity plotted for each group over time (Cholesterol)




Fig.30(Luciferase activity plotted for each group over time Cholesterol)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

Luciferase activity plotted for each group over time (DSPC)




Fig.31 (Luciferase activity plotted for each group over time DSPC)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

Top Bright Field Bottom Fundus Images  
After 7 Days (**Cholesterol**)




Fig.32 (Representative bright light top and td Tomato bottom fundus images for each group taken 7 days post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

Top Bright Field Bottom Fundus Images  
After 7 Days (**DSPC**)




Fig.34 (Representative bright light top and td Tomato bottom fundus images for each group taken 7 days post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

Confocal Image of Immunohistochemistry  
(**Cholesterol**)




Fig.33 (Representative confocal images of immunohistochemistry showing RFP expression in the REP for all groups)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

Confocal Image of Immunohistochemistry  
(**DSPC**)




Fig.35 (Representative confocal images of immunohistochemistry showing RFP expression in the REP for all groups)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

To determine the location of protein expression in the eye



Luciferase mRNA + Cre mRNA was injected subretinally to Ai9 Mice



**What do you expect?**



Ai9 Mice

Prevent transcription of red fluorescent protein variant td Tomato




Fig.36 (Representative image demonstrating Luciferase activity in C57BL/6 and apoE eyes 24 hours post-injection)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye




Fig.37 (Representative confocal images of immunohistochemistry showing mCherry expression in the RPE)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

To verifying that neither phagocytosis nor apoE adsorption are responsible for LNP intracellular delivery the RPE



# Conclusion

- The particles with less PEG (0.5%) and larger in size (150nm) facilitates the highest level of protein expression post-subretinal and intravitreal delivery
- LNPs can transfect Muller glia, the ONH and the TM post-intravitreal delivery which could have significant impacts for retinal degeneration and glaucoma




Fig.38 (Representative confocal images of immunohistochemistry showing RFP expression in the REP for all groups)  
Source: Research Article The Effects of PEGylation on LNP Based mRNA Delivery to the Eye

What is the different between LNPs approach and viral delivery system for gene therapy?

# References

- The effects of PEGylation on LNP based mRNA delivery to the eye by Renee C. Ryals, Siddharth Patel, Chris Acosta, Madison McKinney, Mark E. Pennesi and Gaurav Sahay. Health & Science University, Portland. Department of Pharmaceutical Sciences, United State of America.  
October 29, 2020